Expertise in
16
conditions

Dr. Sana Karam

Radiation Oncology
Washington University School Of Medicine
4921 Parkview Pl, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 1 Trial
17 Years of Experience
Expertise in
16
conditions
Washington University School Of Medicine
4921 Parkview Pl, 
Saint Louis, MO 

Overview

Sana Karam is a Radiation Oncologist in Saint Louis, Missouri. Dr. Karam has been practicing medicine for over 17 years is highly rated in 16 conditions, according to our data. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngeal Cancer, Oral Squamous Cell Carcinoma, and Pancreatectomy.

Her clinical research consists of co-authoring 166 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year

2009

Specialties

Radiation Oncology

Licenses

Radiology in MO

Hospital Affiliations

Barnes Jewish Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 3 Less Insurance Carriers -

Locations

Washington University School of Medicine
4921 Parkview Pl, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase I/Ib Trial of Radiotherapy in Combination With Durvalumab (MEDI4736) Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Radiation, Drug, Procedure
Study Drug: Durvalumab
Study Phase: Phase 1
A Phase I/Ib Study of sEphB4-HSA in Combination With Chemotherapy or Cetuximab and Radiation Therapy in Patients With Intermediate to High Risk, Locally-Advanced Squamous Cell Carcinomas of the Head and Neck
A Phase I/Ib Study of sEphB4-HSA in Combination With Chemotherapy or Cetuximab and Radiation Therapy in Patients With Intermediate to High Risk, Locally-Advanced Squamous Cell Carcinomas of the Head and Neck
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug, Radiation
Study Drugs: sEphB4-HAS, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 1
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Phase I/II Trial of Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV-unrelated Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Completed
Publish Date: February 03, 2025
Intervention Type: Drug, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 1
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherapy in Patients With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Enrollment Status: Withdrawn
Publish Date: December 06, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nab-paclitaxel, Paclitaxel, Pembrolizumab
Study Phase: Phase 2
An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment
An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment
Enrollment Status: Completed
Publish Date: May 28, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

166 Total Publications

Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy.
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy.
Journal: Nature reviews. Cancer
Published: December 15, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Perry Grigsby
Radiation Oncology
Expertise in
15
conditions
Dr. Perry Grigsby
Radiation Oncology

Washington University School Of Medicine

4921 Parkview Pl Lowr Level, 
Saint Louis, MO 
 (0.9 miles away)
314-747-7236
Languages Spoken:
English
See accepted insurances

Perry Grigsby is a Radiation Oncologist in Saint Louis, Missouri. Dr. Grigsby is highly rated in 15 conditions, according to our data. His top areas of expertise are Cervical Cancer, Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, and Thyroidectomy.

Expertise in
26
conditions
Dr. Clifford Robinson
Radiation Oncology
Expertise in
26
conditions
Dr. Clifford Robinson
Radiation Oncology

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 miles away)
314-747-7236
Languages Spoken:
English
See accepted insurances

Clifford Robinson is a Radiation Oncologist in Saint Louis, Missouri. Dr. Robinson is highly rated in 26 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Expertise in
8
conditions
Dr. Wade Thorstad
Radiation Oncology
Expertise in
8
conditions
Dr. Wade Thorstad
Radiation Oncology

Washington University School Of Medicine

4921 Parkview Pl Lowr Level, 
Saint Louis, MO 
 (0.9 miles away)
314-747-7236
Languages Spoken:
English
See accepted insurances

Wade Thorstad is a Radiation Oncologist in Saint Louis, Missouri. Dr. Thorstad is highly rated in 8 conditions, according to our data. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Tongue Cancer, and Gastrostomy.

Frequently Asked Questions about Dr. Sana Karam

How do I make an appointment with Dr. Sana Karam?

You can book an appointment with Dr. Sana Karam by calling their office at 314-747-7236. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sana Karam a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sana Karam is classified as an Distinguished expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sana Karam specialize in?

While Dr. Sana Karam is a Radiation Oncology, they have specific expertise in Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, and Laryngeal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Sana Karam participate in research or clinical trials?

Yes. Dr. Sana Karam has published 166 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Dr. Sana Karam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sana Karam accept my insurance?

Dr. Sana Karam accepts most major insurance plans, including Aetna and Humana. We recommend calling the office directly at 314-747-7236 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karam's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile